AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Aug 2022 03:00 PM
RNS
Total Voting Rights
29 Jul 2022 07:01 AM
RNS
Chair succession
29 Jul 2022 07:00 AM
RNS
Half-year Report
25 Jul 2022 07:10 AM
RNS
Tezspire recommended for EU approval in asthma
25 Jul 2022 07:05 AM
RNS
Ultomiris recommended for EU approval for gMG
25 Jul 2022 07:00 AM
RNS
Enhertu granted Priority Review for HER2-low mBC
19 Jul 2022 07:00 AM
RNS
Enhertu approved in EU for HER2-positive mBC
05 Jul 2022 07:00 AM
RNS
AstraZeneca to acquire TeneoTwo and T cell engager
01 Jul 2022 03:00 PM
RNS
Total Voting Rights
30 Jun 2022 07:00 AM
RNS
Imfinzi improved pCR in resectable lung cancer
27 Jun 2022 07:05 AM
RNS
Enhertu recommended for breast cancer EU approval
27 Jun 2022 07:00 AM
RNS
Lynparza recommended in EU for early breast cancer
21 Jun 2022 07:00 AM
RNS
Eplontersen Ph III trial met co-primary endpoints
06 Jun 2022 07:00 AM
RNS
Enhertu efficacy results in HER2-low breast cancer
01 Jun 2022 03:00 PM
RNS
Total Voting Rights
01 Jun 2022 03:00 PM
RNS
Block listing Interim Review
20 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
09 May 2022 01:00 PM
RNS
Appointment of joint corporate brokers
06 May 2022 04:00 PM
RNS
Director/PDMR Shareholding
05 May 2022 07:10 AM
RNS
Enhertu approved in US for 2L HER2+ breast cancer
05 May 2022 07:05 AM
RNS
Farxiga HFpEF Phase III trial met primary endpoint
05 May 2022 07:00 AM
RNS
Ultomiris NMOSD Ph. III trial met primary endpoint
04 May 2022 07:00 AM
RNS
Imfinzi combo granted Priority Review for BTC
03 May 2022 03:00 PM
RNS
Total Voting Rights
29 Apr 2022 05:30 PM
RNS
Result of AGM
29 Apr 2022 07:05 AM
RNS
AstraZeneca plans new R&D centre in Massachusetts
29 Apr 2022 07:00 AM
RNS
First quarter 2022 results
28 Apr 2022 07:00 AM
RNS
Ultomiris approved in the US for adults with gMG
27 Apr 2022 07:00 AM
RNS
Enhertu granted BTD for HER2-low breast cancer
25 Apr 2022 07:00 AM
RNS
Tremelimumab US Priority Review for Imfinzi combo
19 Apr 2022 07:00 AM
RNS
Enhertu granted Priority Review for HER2m NSCLC
01 Apr 2022 03:00 PM
RNS
Total Voting Rights
29 Mar 2022 07:00 AM
RNS
Ondexxya approved in Japan for FXai reversal
28 Mar 2022 07:00 AM
RNS
Evusheld approved in the EU for COVID-19
25 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
24 Mar 2022 06:00 PM
RNS
Evusheld Positive EU CHMP Opinion
24 Mar 2022 07:00 AM
RNS
Update on CALLA Phase III trial for Imfinzi
23 Mar 2022 11:00 AM
RNS
Notice of AGM
17 Mar 2022 07:00 AM
RNS
Settlement of patent litigation for Ultomiris
14 Mar 2022 07:05 AM
RNS
Lynparza approved in US for early breast cancer
14 Mar 2022 07:00 AM
RNS
Update on US review of Fasenra in nasal polyps
09 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
07 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:30 PM
RNS
Director/PDMR Shareholding
01 Mar 2022 03:00 PM
RNS
Total Voting Rights
01 Mar 2022 07:00 AM
RNS
AstraZeneca and Neurimmune close deal for NI006
23 Feb 2022 07:00 AM
RNS
Filing of Form 20-F with SEC
22 Feb 2022 11:00 AM
RNS
Chair succession planning update and Annual Report
21 Feb 2022 07:00 AM
RNS
Enhertu improves PFS and OS in HER2-low BC
16 Feb 2022 07:00 AM
RNS
Saphnelo approved in EU for SLE

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings